Preclinical studies have suggested that monoamine oxidase A (MAO-A) inhibitors and SSRIs may influence the tumor microenvironment exerting a synergistic cytotoxic effect with anti-PD-1 therapy on cancer cells (61–63). Here, PDCD1 is linked to neoplasm.